Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: Anti-Xa and anti-IIa profiles

Summary

The development of heparin oral form has been a subject of international research for a long time. Promising results have been obtained in vivo in terms of anti-Xa activity with different strategies and notably microparticles but studies concerning the anti-IIa activity and the anti-Xa/anti-IIa ratio have never been presented. Anti-Xa activities, anti-IIa activities and anti-Xa/anti-IIa ratios provided by nadroparin Eudragit^→ RS and poly (D,L-lactic-co-glycolic acid) (PLGA) microparticles were determined in vitro and in vivo and an evaluation of their pharmacokinetic parameters compared to subcutaneous injection was performed. Nadroparin was encapsulated into microparticles prepared by the double emulsion method using Eudragit^→ RS alone or in mixture with PLGA of two kinds, i.e. with (PLGA S) or without (PLGA H) esterification of the acid ending. Microparticles characterisation was performed (size, anti-Xa and anti-IIa activities entrapped and released) before their oral administration in rabbits. In vitro anti-Xa/anti-IIa ratios released from nadroparin microparticles were higher than the ratio of the commercial solution. After oral administration, whatever the formulation, sustained anti-Xa and anti-IIa activities were obtained compared to the subcutaneous injection with a peak concentration at 4 hours (up to 0.59 anti-Xa U/ml and 0.11 anti-IIa U/ml for PLGA S 50% / ERS 50% formulation). Anti-Xa and anti-IIa relative bioavailabilities were high, up to 40% (ERS 100% formulation). Anti-Xa/anti-IIa ratios were within range already obtained for subcutaneous injection, i.e. between 5 and 15. Nadroparin microparticles of nadroparin are promising oral dosage form performing sustained and well controlled anti-Xa, anti-IIa activities and anti-Xa/anti-IIa ratio.

Keywords

LMWH - microparticles - anti-Xa/anti-IIa ratio - oral administration

• References

• 1 Schindewolf M, Schwaner S, Wolter M. et al. Incidence and causes of heparin-induced skin lesions. CMAJ 2009; 181: 477-481.
• 2 Gaigl Z, Pfeuffer P, Raith P. et al. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 2005; 128: 389-392.
• 3 Motlekar NA, Youan BB. The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins. J Control Release 2006; 113: 91-101.
• 4 Kim SK LD, Lee E, Lee YK. et al. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release 2007; 120: 4-10.
• 5 Hoffart V, Lamprecht A, Maincent P. et al. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release 2006; 113: 38-42.
• 6 Jiao Y, Ubrich N, Hoffart V. et al. Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J Pharm Sci 2002; 91: 760-768.
• 7 Thanou M, Verhoef JC, Nihot MT. et al. Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P. Pharm Res 2001; 18: 1638-1641.
• 8 Bernkop-Schnurch A, Kast CE, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 2003; 93: 95-103.
• 9 Schmitz T, Leitner VM, Bernkop-Schnurch A. Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. J Pharm Sci 2005; 94: 966-973.
• 10 Thanou M, Henderson S, Kydonieus A. et al. N-sulfonato-N,O-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release 2007; 117: 171-178.
• 11 Scala-Bertola J, Rabiskova M, Lecompte T. et al. Granules in the improvement of oral heparin bioavailability. Int J Pharm 2009; 374: 12-16.
• 12 Scala-Bertola J, Gajdziok J, Rabiskova M. et al. Pellets for oral administration of low-molecular-weight heparin. Drug Dev Ind Pharm 2009; 35: 1503-1510.
• 13 Choay J. Structure and activity of heparin and its fragments: an overview. Semin Thromb Hemost 1989; 15: 359-364.
• 14 Hemker HC, Beguin S. Mode of Action of Low-Molecular-weight Heparins in Plasma and Its Consequances for the Clinical Laboratory. In: Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases (fundamental clinical cardiology series). Editions Medicales Inter-nationales; 1994: 21-42.
• 15 Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.
• 16 Gerotziafas GT, Petropoulou AD, Verdy E. et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 05: 955-962.
• 17 Javot L, Lecompte T, Rabiskova M. et al. Encapsulation of low molecular weight heparins: Influence on the anti-Xa/anti-IIa ratio. J Control Release 2009; 139: 8-14.
• 18 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410.
• 19 Chernyshera YV, Babak VG, Kildeeva NR. et al. Effect of the type of hydrophobic polymers on the size of nanoparticles obtained by emulsification-solvent evaporation. Mendeleev Comm 2003; 02: 65-68.
• 20 Hoffart V, Ubrich N, Simonin C. et al. Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release characteristics. Drug Dev Ind Pharm 2002; 28: 1091-1099.
• 21 Hoffart V, Ubrich N, Lamprecht A. et al. Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers. Drug Deliv 2003; 10: 1-7.
• 22 Jiao Y, Ubrich N, Marchand-Arvier M. et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002; 105: 230-235.
• 23 Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41: 391-412.
• 24 Tracy MA, Ward KL, Firouzabadian L. et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999; 20: 1057-1062.
• 25 Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur J Pharm Sci 2006; 27: 143-149.
• 26 Friess W, Schlapp M. Release mechanisms from gentamicin loaded poly(lactic-coglycolic acid) (PLGA) microparticles. J Pharm Sci 2002; 91: 845-855.
• 27 Jaklenec A, Hinckfuss A, Bilgen B. et al. Sequential release of bioactive IGF-I and TGF-beta 1 from PLGA microsphere-based scaffolds. Biomaterials 2008; 29: 1518-1525.
• 28 Chhabra S, Sachdeva V, Singh S. Influence of end groups on in vitro release and biological activity of lysozyme from a phase-sensitive smart polymer-based in situ gel forming controlled release drug delivery system. Int J Pharm 2007; 342: 72-77.
• 29 Hirsh J, Bauer KA, Donati MB. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 141-159.
• 30 Hetzel GR, Sucker C. The heparins: all a nephrologist should know. Nephrol Dial Transplant 2005; 20: 2036-2042.
• 31 Jandik KA, Kruep D, Cartier M. et al. Accelerated stability studies of heparin. J Pharm Sci 1996; 85: 45-51.
• 32 Ahn MY, Shin KH, Kim DH. et al. Characterization of a Bacteroides species from human intestine that degrades glycosaminoglycans. Can J Microbiol 1998; 44: 423-429.
• 33 Davies RR, Davies JA. Rabbit gastrointestinal physiology. Vet Clin North Am Exot Anim Pract 2003; 06: 139-153.
• 34 O’Hagan DT. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat 1996; 189: 477-482.
• 35 Lamprecht A, Koenig P, Ubrich N. et al. Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells. Nanotechnology 2006; 17: 3673-3680.
• 36 Bianchini P, Bergonzini GL, Parma B. et al. Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass. Haemostasis 1995; 25: 288-298.
• 37 Al Dieri R, Alban S, Beguin S. et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 02: 1395-1401.
• 38 Al Dieri R, Wagenvoord R, van Dedem GW. et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif--the C-domain. J Thromb Haemost 2003; 01: 907-914.
• 39 Petereit HU, Weisbrod W. Formulation and process considerations affecting the stability of solid dosage forms formulated with methacrylate copolymers. Eur J Pharm Biopharm 1999; 47: 15-25.
• 40 Fu K, Pack DW, Klibanov AM. et al. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 2000; 17: 100-106.
• 41 Mader K, Bittner B, Li Y. et al. Monitoring microviscosity and microacidity of the albumin microenvironment inside degrading microparticles from poly(lactideco-glycolide) (PLG) or ABA-triblock polymers containing hydrophobic poly(lac-tide-co-glycolide) A blocks and hydrophilic poly(ethyleneoxide) B blocks. Pharm Res 1998; 15: 787-793.
• 42 Shenderova A, Burke TG, Schwendeman SP. The acidic microclimate in poly(lac-tide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res 1999; 16: 241-248.
• 43 Li L, Schwendeman SP. Mapping neutral microclimate pH in PLGA microspheres. J Control Release 2005; 101: 163-173.